Literature DB >> 16231045

Validation overview of bio-analytical methods.

M Tuomela1, I Stanescu, K Krohn.   

Abstract

Several regulatory challenges are encountered when proceeding towards human clinical trials with gene therapy products, one of these relating to the validity of the analytical methods. Many of the analytical methods used in preclinical studies and/or for analysing the gene therapy products are not yet recognized as a standardized pharmacopoeial methods. Thus, their validity should be demonstrated for the regulatory authorities by thorough assay validations, the extent being dependent on the product developmental stage. We hereby provide an overview on the critical parameters that have to be taken into consideration during the optimization and validation of bio-analytical methods such as PCR, enzyme-linked immunospot assay, Microarray and Limulus Amebocyte Lysate analyses.

Entities:  

Mesh:

Year:  2005        PMID: 16231045     DOI: 10.1038/sj.gt.3302627

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

2.  Therapeutic DNA vaccine reduces schistosoma mansoni-induced tissue damage through cytokine balance and decreased migration of myofibroblasts.

Authors:  Fabiani Gai Frantz; Toshihiro Ito; Karen Angélica Cavassani; Cory M Hogaboam; Célio Lopes Silva; Steven L Kunkel; Lúcia H Faccioli
Journal:  Am J Pathol       Date:  2011-05-18       Impact factor: 4.307

3.  Library of molecular associations: curating the complex molecular basis of liver diseases.

Authors:  Stefan Buchkremer; Jasmin Hendel; Markus Krupp; Arndt Weinmann; Kai Schlamp; Thorsten Maass; Frank Staib; Peter R Galle; Andreas Teufel
Journal:  BMC Genomics       Date:  2010-03-20       Impact factor: 3.969

Review 4.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506

5.  An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.

Authors:  Sascha Barabas; Theresa Spindler; Richard Kiener; Charlotte Tonar; Tamara Lugner; Julia Batzilla; Hanna Bendfeldt; Anne Rascle; Benedikt Asbach; Ralf Wagner; Ludwig Deml
Journal:  BMC Immunol       Date:  2017-03-07       Impact factor: 3.615

6.  The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells.

Authors:  Rachel Tanner; Emily Hoogkamer; Julia Bitencourt; Andrew White; Charelle Boot; Claudia C Sombroek; Stephanie A Harris; Matthew K O'Shea; Daniel Wright; Rachel Wittenberg; Charlotte Sarfas; Iman Satti; Frank A W Verreck; Sally A Sharpe; Helen A Fletcher; Helen McShane
Journal:  F1000Res       Date:  2021-03-30

7.  A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.

Authors:  Rachel Tanner; Andrew D White; Charelle Boot; Claudia C Sombroek; Matthew K O'Shea; Daniel Wright; Emily Hoogkamer; Julia Bitencourt; Stephanie A Harris; Charlotte Sarfas; Rachel Wittenberg; Iman Satti; Helen A Fletcher; Frank A W Verreck; Sally A Sharpe; Helen McShane
Journal:  NPJ Vaccines       Date:  2021-01-04       Impact factor: 7.344

8.  Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Authors:  Helen A Fletcher; Rachel Tanner; Robert S Wallis; Joel Meyer; Zita-Rose Manjaly; Stephanie Harris; Iman Satti; Richard F Silver; Dan Hoft; Beate Kampmann; K Barry Walker; Hazel M Dockrell; Uli Fruth; Lew Barker; Michael J Brennan; Helen McShane
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

9.  The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets.

Authors:  Tracy L Hartman; Robert W Buckheit
Journal:  Mol Biol Int       Date:  2012-07-10

10.  Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).

Authors:  Sylvia Janetzki; Katherine S Panageas; Leah Ben-Porat; Jean Boyer; Cedrik M Britten; Timothy M Clay; Michael Kalos; Holden T Maecker; Pedro Romero; Jianda Yuan; W Martin Kast; Axel Hoos
Journal:  Cancer Immunol Immunother       Date:  2007-08-25       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.